Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
Conditions
Interventions
Intervention1: DRUG - ITRACONAZOLE: THREE DIFFERENT DOSES 100, 200 AND 400MG COMPARED
DURATION: till clinical and mycological cure
Frequency of administration
100mg : OD
200mg: OD
400mg : given as 20
Sponsors
none
Eligibility
Inclusion criteria
Inclusion criteria: 180 consenting adult patients with a diagnosis of Tinea cruris and/or corporis, on clinical examination with confirmation by KOH microscopy, who would require systemic treatment as per the assessment of the examining physician.
Exclusion criteria
Exclusion criteria: a) Those on any regular systemic drug or with any pre-existing systemic disease. b) Those with history of drug induced hepatotoxicity or ventricular dysfunction. c) Those with deranged baseline liver function tests. d) Those with a history of a hypersensitivity reaction to itraconazole before. e) Pregnant and lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To evaluate the treatment duration required to achieve clinical and mycological cure with each dose of itraconazole (100mg/day, 200mg/day and 400 mg/day) in patients with tinea corporis and cruris. 2. To compare the clinical and mycological efficacy of the three regimens of itraconazole with the comparator group treated with terbinafine. 3. To assess the safety profile of the three itraconazole regimens. Timepoint: By 30th June 2020 | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical correlation of MIC data with response to the three regimens of itraconazoleTimepoint: By 30th June 2020 | — |
Countries
India
Contacts
Public ContactAnanta Khurana
Dr RML hospital and ABVIMS.
Outcome results
None listed